S Müller1, D Poehnert, J A Müller, G W F Scheumann, M Koch, R Lück. 1. Allgemein-, Viszeral- und Transplantationschirurgie, Medizinische Hochschule Hannover, Carl-Neuberg-Str. 1, 30175, Hannover, Germany. S.a.r.a.h.Mueller@web.de
Abstract
BACKGROUND: Immunological response of the human body is controlled by the suppressive characteristics of regulatory T cells (Tregs). In various diseases a change in the number of Tregs is evident. For example, whereas Tregs are reduced in auto-immunological processes, an increase of Tregs is found with various malignant tumors. Regarding medullary thyroid carcinoma (MTC) no such studies have been performed to date. METHODS: Expression of CD4 and CD25 in CD45+ leukocytes from blood and lymph nodes was studied by flow cytometry in patients with MTC and patients with benign goiter. We also examined the marker forkhead box P3 (FoxP3), an intracellular transcription factor, which is supposed to be the most specific marker for Tregs. Immunohistochemical staining for FoxP3 was performed on lymph node and thyroid tissue. RESULTS: The number of FoxP3+ lymphocytes in peripheral blood was significantly higher in patients with MTC than in controls (p = 0.02). This result was confirmed immunohistochemically in lymph node and thyroid tissue, as well as in carcinoma tissue. No difference in CD4+CD25+ lymphocytes was observed between the two groups. After clinical staging (International Union against Cancer-UICC-stages) of MTC patients, triplication of FoxP3+ lymphocytes could be observed from MTC < UICC II to MTC > UICC II. CONCLUSIONS: An increase of FoxP3+ lymphocytes could be shown in peripheral blood of patients with MTC but not in patients with benign goiter; this increase also correlates with findings in lymph nodes and thyroid gland. The number of FoxP3+ cells correlated with the patients' prognosis. Therefore, FoxP3+ lymphocytes are a good diagnostic criterion for malignancy in patients with medullary thyroid carcinoma, and their presence at staging may influence therapeutic decisions.
BACKGROUND: Immunological response of the human body is controlled by the suppressive characteristics of regulatory T cells (Tregs). In various diseases a change in the number of Tregs is evident. For example, whereas Tregs are reduced in auto-immunological processes, an increase of Tregs is found with various malignant tumors. Regarding medullary thyroid carcinoma (MTC) no such studies have been performed to date. METHODS: Expression of CD4 and CD25 in CD45+ leukocytes from blood and lymph nodes was studied by flow cytometry in patients with MTC and patients with benign goiter. We also examined the marker forkhead box P3 (FoxP3), an intracellular transcription factor, which is supposed to be the most specific marker for Tregs. Immunohistochemical staining for FoxP3 was performed on lymph node and thyroid tissue. RESULTS: The number of FoxP3+ lymphocytes in peripheral blood was significantly higher in patients with MTC than in controls (p = 0.02). This result was confirmed immunohistochemically in lymph node and thyroid tissue, as well as in carcinoma tissue. No difference in CD4+CD25+ lymphocytes was observed between the two groups. After clinical staging (International Union against Cancer-UICC-stages) of MTC patients, triplication of FoxP3+ lymphocytes could be observed from MTC < UICC II to MTC > UICC II. CONCLUSIONS: An increase of FoxP3+ lymphocytes could be shown in peripheral blood of patients with MTC but not in patients with benign goiter; this increase also correlates with findings in lymph nodes and thyroid gland. The number of FoxP3+ cells correlated with the patients' prognosis. Therefore, FoxP3+ lymphocytes are a good diagnostic criterion for malignancy in patients with medullary thyroid carcinoma, and their presence at staging may influence therapeutic decisions.
Authors: M L Brandi; R F Gagel; A Angeli; J P Bilezikian; P Beck-Peccoz; C Bordi; B Conte-Devolx; A Falchetti; R G Gheri; A Libroia; C J Lips; G Lombardi; M Mannelli; F Pacini; B A Ponder; F Raue; B Skogseid; G Tamburrano; R V Thakker; N W Thompson; P Tomassetti; F Tonelli; S A Wells; S J Marx Journal: J Clin Endocrinol Metab Date: 2001-12 Impact factor: 5.958
Authors: Michael A Skinner; Jeffrey A Moley; William G Dilley; Kouros Owzar; Mary K Debenedetti; Samuel A Wells Journal: N Engl J Med Date: 2005-09-15 Impact factor: 91.245
Authors: C Eng; D Clayton; I Schuffenecker; G Lenoir; G Cote; R F Gagel; H K van Amstel; C J Lips; I Nishisho; S I Takai; D J Marsh; B G Robinson; K Frank-Raue; F Raue; F Xue; W W Noll; C Romei; F Pacini; M Fink; B Niederle; J Zedenius; M Nordenskjöld; P Komminoth; G N Hendy; L M Mulligan Journal: JAMA Date: 1996-11-20 Impact factor: 56.272
Authors: Tyler J Curiel; George Coukos; Linhua Zou; Xavier Alvarez; Pui Cheng; Peter Mottram; Melina Evdemon-Hogan; Jose R Conejo-Garcia; Lin Zhang; Matthew Burow; Yun Zhu; Shuang Wei; Ilona Kryczek; Ben Daniel; Alan Gordon; Leann Myers; Andrew Lackner; Mary L Disis; Keith L Knutson; Lieping Chen; Weiping Zou Journal: Nat Med Date: 2004-08-22 Impact factor: 53.440
Authors: Patricia Niccoli-Sire; Arnaud Murat; Vincent Rohmer; Hélène Gibelin; Gerard Chabrier; Bernard Conte-Devolx; Jacques Visset; Jean Ronceray; Daniel Jaeck; Jean François Henry; Charles Proye; Bruno Carnaille; Jean Louis Kraimps Journal: Surgery Date: 2003-12 Impact factor: 3.982
Authors: Sebastian Hinz; Laia Pagerols-Raluy; Hans-Heinrich Oberg; Ole Ammerpohl; Sandra Grüssel; Bence Sipos; Robert Grützmann; Christian Pilarsky; Hendrik Ungefroren; Hans-Detlev Saeger; Günter Klöppel; Dieter Kabelitz; Holger Kalthoff Journal: Cancer Res Date: 2007-09-01 Impact factor: 12.701
Authors: Scott J Roberts; Bernice Y Ng; Renata B Filler; Julia Lewis; Earl J Glusac; Adrian C Hayday; Robert E Tigelaar; Michael Girardi Journal: Proc Natl Acad Sci U S A Date: 2007-04-05 Impact factor: 11.205
Authors: Ilona Kryczek; Rebecca Liu; Guobin Wang; Ke Wu; Xiaogong Shu; Wojciech Szeliga; Linhua Vatan; Emily Finlayson; Emina Huang; Diane Simeone; Bruce Redman; Theodore H Welling; Alfred Chang; Weiping Zou Journal: Cancer Res Date: 2009-04-21 Impact factor: 12.701
Authors: Khoon Lin Ling; Sarah E Pratap; Gaynor J Bates; Baljit Singh; Neil J Mortensen; Bruce D George; Bryan F Warren; Juan Piris; Giovanna Roncador; Stephen B Fox; Alison H Banham; Vincenzo Cerundolo Journal: Cancer Immun Date: 2007-03-28
Authors: Naseem Akhter; Raed A Alharbi; Abdulmajeed A A Sindi; Mohammad Zeeshan Najm; Fahad A Alhumaydhi; Mohammad Aasif Khan; S V S Deo; Syed Akhtar Husain Journal: Front Genet Date: 2021-11-29 Impact factor: 4.599
Authors: Jaydira Del Rivero; Renee N Donahue; Jennifer L Marté; Ann W Gramza; Marijo Bilusic; Myrna Rauckhorst; Lisa Cordes; Maria J Merino; William L Dahut; Jeffrey Schlom; James L Gulley; Ravi A Madan Journal: Front Endocrinol (Lausanne) Date: 2020-08-07 Impact factor: 5.555